Patient dies following muscular dystrophy gene therapy, Sarepta reports
The young man died of acute liver injury, a known side effect, Sarepta said in a statement. But the company said the “severity” of the patient’s case had not previously been seen with the therapy, ...
Sarepta Therapeutics stock falls after DMM patient dies of liver failure
Sarepta Therapeutics Inc.’s stock was down 21.6% in premarket trades on Tuesday after the commercial-stage biopharmaceutical company said a patient died from liver failure after using its drug ...
Gene Therapy Maker Tanks After Patient Death
Sarepta Therapeutics' shares have struggled for the past year due to concerns about the commercial potential of its gene therapy and broader pipeline. Safety hadn’t been a major worry for investors—pa ...
Sarepta discloses patient death after gene therapy treatment
Sarepta Therapeutics said on Tuesday a young man has died due to acute liver failure after treatment with its gene therapy for a rare muscular dystrophy. Shares of the company plummeted more than 25% ...
Sarepta Therapeutics Hits 52-Week Low After Patient Death
Shares of Sarepta Therapeutics fell after the company said a patient with Duchenne muscular dystrophy died of liver failure after using its Elevidys treatment. The stock opened the market down 22% at ...
Roche to present new data at MDA conference on Evrysdi
Roche (RHHBY) announced that it will present new data at the Muscular Dystrophy Association, MDA conference, 16-19 March, 2025, in Dallas, ...
Sarepta initiated with a Sector Perform at Scotiabank
Scotiabank analyst Louise Chen initiated coverage of Sarepta (SRPT) with a Sector Perform rating and $105 price target The firm says that ...
Sarepta Therapeutics’ stock falls after patient dies of liver failure
Sarepta Therapeutics Inc.’s stock was down 21.6% in premarket trades on Tuesday after the commercial-stage biopharmaceutical company said a patient died from liver failure after using its drug ...